Related Experiment Video
Updated: Feb 11, 2026

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
Published on: February 10, 2023
Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung
Sander Bins1, Edwin A Basak1, Samira El Bouazzaoui2
1Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, Rotterdam, 3008 AE, The Netherlands.
Background:
Treatment with PD-1 inhibitors can be hampered by severe auto-immune-related toxicities. Our objective was to identify single-nucleotide polymorphisms (SNPs) in genes previously associated with auto-immunity, which are associated with toxicities in nivolumab-treated NSCLC patients. This was in order to identify patients prone to develop severe toxicities and to gain more insight into the underlying pathobiology.
Methods:
We analysed 322 nivolumab-treated patients and assessed the association with toxicities for seven SNPs in four genes, which are considered contributors to PD-1-directed T-cell responses, i.e., PDCD1, PTPN11, ZAP70 and IFNG. Every SNP was tested for its association with toxicity endpoints. Significant associations were tested in a validation cohort.
Results:
A multivariable analysis in the exploration cohort showed that homozygous variant patients for PDCD1 804C>T (rs2227981) had decreased odds for any grade treatment-related toxicities (n = 96; OR 0.4; 95% CI 0.2-1.0; p = 0.039). However, this result could not be validated (n = 85; OR 0.9; 95% CI 0.4-1.9; p = NS).
Conclusions:
Our results show that it is unlikely that the investigated SNPs have a clinical implication in predicting toxicity. A finding, even though negative, that is considered timely and instructive towards further research in biomarker development for checkpoint inhibitor treatments.
Insights
Investigating single-nucleotide polymorphisms (SNPs) in PD-1 inhibitor-treated NSCLC patients did not predict treatment toxicities. This research provides insights for future biomarker development in immunotherapy.
Area of Science:
- Immunogenetics
- Oncology
- Pharmacogenomics
Background:
- Immune checkpoint inhibitors (ICIs), such as PD-1 inhibitors, are crucial in cancer treatment but can cause severe immune-related adverse events.
- Identifying patients at risk for these toxicities is essential for safe and effective immunotherapy.
Purpose of the Study:
- To identify single-nucleotide polymorphisms (SNPs) associated with treatment-related toxicities in non-small cell lung cancer (NSCLC) patients receiving nivolumab.
- To explore the pathobiology underlying these toxicities and aid in patient risk stratification.
Main Methods:
- A cohort of 322 nivolumab-treated NSCLC patients was analyzed.
- Seven SNPs in four genes (PDCD1, PTPN11, ZAP70, IFNG) involved in PD-1 signaling were assessed for association with toxicity.
- Significant findings were validated in a separate cohort.
Main Results:
- In the initial cohort, homozygous variant carriers of PDCD1 804C>T (rs2227981) showed reduced odds of any-grade toxicity (OR 0.4; P=0.039).
- This association was not replicated in the validation cohort (OR 0.9; P=NS).
Conclusions:
- The investigated SNPs are unlikely to have clinical utility in predicting nivolumab-induced toxicities.
- These negative findings are valuable for guiding future research in developing predictive biomarkers for ICI therapy.
Related Concept Videos
Single Nucleotide Polymorphisms-SNPs
Nucleotide Excision Repair
Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Cancers Originate from Somatic Mutations in a Single Cell
Lung Capacity
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...

